AZD0292 for Bronchiectasis with Pseudomonas Aeruginosa Colonization
This study is testing a new medicine called AZD0292 to see if it can help people aged 12 and older who have bronchiectasis (a lung condition where airways are widened and scarred) and chronic Pseudomonas Aeruginosa (a type of bacteria) infection. AZD0292 is given through an IV (into a vein). Some participants will receive a high dose, some a low dose, and others a placebo (an inactive substance). The main goal is to see if AZD0292 can reduce the number of lung flare-ups (exacerbations) over a period of 28 to 52 weeks. To join, you must be at least 12 years old, weigh at least 35 kg, and have bronchiectasis confirmed by a doctor and a CT scan. The study is currently not clear on its recruitment status and plans to enroll 435 participants.
- Study design
- This is an interventional study comparing two doses of AZD0292 to a placebo. It plans to enroll 435 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for a variable time, with the primary endpoint measured between 28 and 52 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
At a glance
Conditions
Where it's being run
187 sites across 42 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Annualized rate of exacerbations over a variable follow-up timeMin 28 weeks, max 52 weeks
To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to-severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA.